"Global leader in cellular medicines for inflammatory diseases"
I've thought for a long time our cells were the natural follow on from the current biologics when there are now so many refractory cases. This was imo in the subtext of SI's comment that GvHD was the "mother of all inflammation". The webcast where SI said the worst cases respond the best to our cells, was the first time I saw MSB as a company, rather than great science.
I'm reading about newer drugs in journals and lacklustre results are attributed to the number of patients refractory to multiple biologics, whereas those are the cases said to respond best to our cells.
.
Ann: Mesoblast Appoints Leading Pharma Industry Executive as CMO, page-11
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |